Kjeldsen Keld
Laboratory for Molecular Cardiology, Medical Department B, The Heart Centre, Copenhagen University Hospital (Rigshospitalet) and Danish National Research Foundation Centre for Cardiac Arrhythmia, University of Copenhagen, Copenhagen, Denmark.
Exp Clin Cardiol. 2010 Winter;15(4):e96-9.
Worldwide, approximately three million people suffer sudden cardiac death annually. These deaths often emerge from a complex interplay of substrates and triggers. Disturbed potassium homeostasis among heart cells is an example of such a trigger. Thus, hypokalemia and, also, more transient reductions in plasma potassium concentration are of importance. Hypokalemia is present in 7% to 17% of patients with cardiovascular disease. Furthermore, up to 20% of hospitalized patients and up to 40% of patients on diuretics suffer from hypokalemia. Importantly, inadequate management of hypokalemia was found in 24% of hospitalized patients. Hypokalemia is associated with increased risk of arrhythmia in patients with cardiovascular disease, as well as increased all-cause mortality, cardiovascular mortality and heart failure mortality by up to 10-fold. Long-term potassium homeostasis depends on renal potassium excretion. However, skeletal muscles play an important role in short-term potassium homeostasis, primarily because skeletal muscles contain the largest single pool of potassium in the body. Moreover, due to the large number of Na(+)/K(+) pumps and K(+) channels, the skeletal muscles possess a huge capacity for potassium exchange. In cardiovascular patients, hypokalemia is often caused by nonpotassium-sparing diuretics, insufficient potassium intake and a shift of potassium into stores by increased potassium uptake stimulated by catecholamines, beta-adrenoceptor agonists and insulin. Interestingly, drugs with a proven significant positive effect on mortality and morbidity rates in heart failure patients all increase plasma potassium concentration. Thus, it may prove beneficial to pay more attention to hypokalemia and to maintain plasma potassium levels in the upper normal range. The more at risk of fatal arrhythmia and sudden cardiac death a patient is, the more attention should be given to the potassium homeostasis.
在全球范围内,每年约有300万人发生心源性猝死。这些死亡往往源于底物和触发因素的复杂相互作用。心脏细胞间钾离子稳态紊乱就是这样一种触发因素。因此,低钾血症以及血浆钾浓度更短暂的降低都很重要。7%至17%的心血管疾病患者存在低钾血症。此外,高达20%的住院患者和高达40%使用利尿剂的患者患有低钾血症。重要的是,在24%的住院患者中发现低钾血症管理不当。低钾血症与心血管疾病患者心律失常风险增加以及全因死亡率、心血管死亡率和心力衰竭死亡率增加高达10倍有关。长期的钾离子稳态依赖于肾脏排钾。然而,骨骼肌在短期钾离子稳态中起重要作用,主要是因为骨骼肌包含体内最大的单一钾离子池。此外,由于大量的钠钾泵和钾离子通道,骨骼肌具有巨大的钾离子交换能力。在心血管疾病患者中,低钾血症常由非保钾利尿剂、钾摄入不足以及儿茶酚胺、β肾上腺素能受体激动剂和胰岛素刺激导致钾摄取增加使钾转移至储存部位引起。有趣的是,对心力衰竭患者死亡率和发病率有显著积极作用的药物都会增加血浆钾浓度。因此,更加关注低钾血症并将血浆钾水平维持在正常上限范围可能是有益的。患者发生致命性心律失常和心源性猝死的风险越高,就越应关注钾离子稳态。